Looking for an advantage in the crowded SMA space, Roche’s Genentech releases fresh Evrysdi data
Roche has been looking for an edge in the SMA race, which so far has been dominated by Biogen’s Spinraza and Novartis’ Zolgensma. And the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
